Immuron to host Live Virtual Event
15 avr. 2024 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, April 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our...
Immuron Travelan® sales continued strong growth
10 avr. 2024 06h00 HE
|
Immuron Limited
Sales Highlights: Global FYTD Mar 2024 AUD$3.6 million up 154% on (prior comparative period) pcpMar 2024 Quarter AUD$1.3 million up 51% on pcp and 75% on last quarter ...
Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US
07 mars 2024 06h00 HE
|
Immuron Limited
Highlights: Immuron proceeding to Phase 3 registration strategy with the FDATravelan® topline clinical trial results demonstrate protective efficacy with single daily dose36.4% protective efficacy...
Immuron Presentation Australian Biologics Festival 2024
21 févr. 2024 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our...
Immuron achieves record Travelan® sales
13 févr. 2024 06h00 HE
|
Immuron Limited
Highlights: Travelan® sales YTD Jan 2024 of $2.7 million exceed peak full year FY20 sales of $2.5 millionAustralian Travelan® YTD Jan 2024 sales $2.1 millionUSA Travelan® YTD Jan 2024 sales $0.6...
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
08 févr. 2024 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief...
Immuron achieves record half yearly Travelan® sales
16 janv. 2024 06h00 HE
|
Immuron Limited
Highlights: Record half yearly Travelan® sales of $2,334,969Total sales of A$2,355,580 in H1, FY24 $1,771,932 increase on H1, FY23 sales51% higher than pre-pandemic period H1, FY20 sales ...
Immuron Clinical Trials Update
22 déc. 2023 06h00 HE
|
Immuron Limited
Highlights: US Naval Medical Research Command (NMRC) campylobacter clinical program completes in-patient phase Manufacture of IMM-529 drug substance to support the Pre-IND information package has...
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study
04 déc. 2023 06h00 HE
|
Immuron Limited
Highlights: First participants enrolled in the US Naval Medical Research Command Clinical Trial Clinical Study initiated to evaluate the efficacy of a new Immuron clinical product to protecting...
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
28 nov. 2023 06h33 HE
|
Immuron Limited
MELBOURNE, Australia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite...